Xeris Biopharma Holdings, Inc. ·
XERS 8-K 2026-09-09
Xeris Biopharma Holdings, Inc. (XERS) 8-K dated 2026-09-09 — accession 0001867096-26-000077. This URL is the filing, not the XERS hub.
Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company listed on US.
Xeris Biopharma Holdings, Inc. filed a 8-K on 2026-09-09. Accession 0001867096-26-000077.
Cached items: 7.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.
Latest reported XERS revenue for 2025-12-31 was $291.8M. Net income was $554.0K. Revenue was up 43.7% from 2024-12-31 to 2025-12-31. XERS currently screens at market cap $760.7M.
Not investment advice. The XERS SEC hub lists recent forms. The stock page is the research view.